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Introduction
The flavin-containing monooxygenases (FMOs; 1.14.13.8) are a family of drug metabolizing enzymes which utilize FAD, NADPH and molecular oxygen to catalyze the oxygenation of a large number of drugs, pesticides and other xenobiotics containing soft nucleophiles (Cashman and Zhang, 2002; Krueger and Williams, 2005) . Generally, FMOs are detoxication catalysts that convert relatively non-polar compounds to more polar metabolites via the incorporation of one atom of molecular oxygen (Ziegler, 1988) .
Eleven human FMO genes have been identified, although only five forms of the enzyme have been shown to be functionally active (Hernandez et al., 2004; Hines et al., 2002) .
Of the five functionally active FMOs, FMO3 (Lomri et al., 1992) and FMO5 (Zhang and Cashman, 2006) appear to be the prominent members in the adult human liver. It is likely that the role in FMO-mediated metabolism by either FMO3 or FMO5 is dependent on the type of substrate presented to the enzyme (Cashman and Zhang, 2006) . For FMO3, certain single nucleotide polymorphisms (SNPs) are associated with significant functional differences in enzyme activity (Cashman and Zhang, 2006) . Certain amines, including drugs, dietary agents and xenobiotics metabolized by FMO3 as a prominent metabolic pathway may be significantly altered if an FMO3 SNP is present (Kang et al., 2000; Cashman et al., 2001; Cashman, 2002; Park et al., 2002) . For example, humans normally N-oxygenate approximately >96.5 % of benzydamine in an FMO3-dependent process. For individuals with defective FMO3, a 2.7-3.3-fold decrease in the average percentage of benzydamine N-oxide formation has been observed (Mayatepek et al., 2004) . The metabolism of trimethylamine (TMA) illustrates another example of a dramatic effect on FMO3-mediated metabolism where individuals that DMD #10827 6 possess defective FMO3 decrease TMA N-oxygenation. Because FMO3 is solely responsible for TMA N-oxygenation in vivo, mutations of FMO3 that cause defective TMA N-oxygenation lead to a rare metabolic disorder called trimethylaminuria (Dolphin et al., 1997; Cashman, 2002a; Cashman et al., 2003) . In addition to rare mutations that cause trimethylaminuria, common SNPs can also decrease FMO3-mediated metabolism and have clinical consequence (Koukouritaki, et al., 2005) . In the case of sulindac and chemoprevention of colorectal cancer, for example, FMO3 SNPs may improve the overall clinical efficacy of the drug. The active sulfide metabolite of sulindac (i.e., sulindac sulfide) is S-oxygenated to the S-oxide and then to the sulfone by FMO3 (Hamman et al., 2000) . SNPs of FMO3 at the E158K and E308G loci decrease functional activity of FMO3 and decrease the retro-oxygenation of sulindac sulfide to inactive sulfoxide and increase the efficacy of sulindac. Among sulindac-treated patients that did not develop familial adenomatous polyposis, 33 % were homogenous for E158K and 17 % were homozygous for E308G variants (Hisamuddin et al., 2004) .
Common FMO3 SNPs vary widely across ethnic groups and it is possible that interethnic variation contributes to therapeutic drug variability for drugs metabolized by FMO3 (Cashman et al., 2001; Furnes et al., 2003) . For example, certain ethnic groups have a much greater prevalence of common FMO3 SNPs and possess a greater incidence of abnormal TMA N-oxygenation (Mitchell et al., 1997) . A rare Leu360Pro FMO3 SNP has only been observed in individuals of African descent (Lattard et al., 2003) . cDNAexpression of the enzyme showed that Pro 360 -FMO3 possessed an extensive metabolizer phenotype in vitro. Thus, mutation of Leu 360 of FMO3 to a Pro is an example of a DMD #10827 9 sonication (i.e., three 2-min bursts separated by periods of cooling). The solution was centrifuged at 18,000 g for 30 min at 4 °C. The resulting supernatant was placed onto an amylose column (New England Bio Lab, Beverly, MA). The pellets were extracted one more time as described above. The resulting supernatant was loaded onto the same amylose column and eluted as described below.
Purification of MBP-FMO-His 6 Fusion Proteins. All purification procedures
were carried out at 4 °C. The resulting supernatants were applied (0.5 ml/min) to an amylose column (35 ml) equilibrated with Buffer A (50 mM Na 2 HPO 4 pH 8.4; 0.5 % Triton X-100). The column was washed with five volumes of Buffer A containing 100 mM flavin adenine dinucleotide. Bound proteins were eluted with 10 mM maltose in Buffer A containing 100 mM flavin adenine dinucleotide. Eluted fractions were then applied to a HisTrap Chelating column (HisTrap Kit; Amersham Biosciences, Piscataway, NJ) equilibrated with buffer B (20 mM phosphate, pH 7.4, 0.5 M NaCl, 10 mM imidazole and 0.5 % Triton X-100) according to the manufacturer's specifications. After washing with buffer B, bound proteins were eluted with 200 mM imidazole in buffer B. Eluted protein was fractionated by SDS-PAGE (Laemmli, 1970) and visualized with Coomasie Blue staining. The fractions containing the bis-fusion protein were pooled and precipitated by adding PEG 500 to achieve a final concentration of 20 % PEG (w:v) and incubated on ice for 30 min. The PEG-precipitated protein was collected by centrifuging at 18,000 rpm for 20 min. The protein was resuspended in buffer A containing 100 mM flavin adenine dinucleotide and 10 % glycerol at 4 °C. The
This article has not been copyedited and formatted. The final version may differ from this version. Enzyme Assays. The oxygenation of MMI was determined by monitoring the oxidation of NADPH associated with S-oxygenation of this substrate (Dixit and Roche, 1984) . The assay contained 50 mM sodium phosphate buffer (pH 8.4), 0.5 mM diethylenetriaminepentaacetic acid (DETAPAC), 0.2 mM NADPH and 0-0.1 mg MBP-FMO-His 6 . Reactions were initiated by the addition of substrate and monitored at 340 nm after obtaining a stable baseline. Kinetic parameters for MMI S-oxygenation were obtained from individual experiments after the addition of decreasing amounts of substrate (1000, 250, 50, 25, 12.5, 6.25, 3 .125 µM final concentration) to the sample cuvette.
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The N-oxygenation of chlorpromazine or 5-DPT was also determined as previously described (Lomri et al., 1993; Brunelle et al., 1997) . Briefly, a typical incubation mixture contained 50 mM potassium phosphate buffer (pH 8.4), 0.4 mM NADP + , 0.4 mM glucose-6-phosphate, 1 IU glucose-6-phosphate dehydrogenase, 0.8 mM DETAPAC and 0-0.9 mg MBP-FMO-His 6 . Reactions were initiated by the addition of 5-DPT or chlorpromazine, incubated at 37 °C for 20 min and stopped by addition of 4 volumes of cold dichloromethane. After addition of 20 mg of Na 2 CO 3 the incubations were mixed and centrifuged to partition metabolites and remaining 5-DPT or chlorpromazine into the organic fraction. The organic fraction was evaporated, dissolved in methanol, mixed thoroughly, centrifuged, and analyzed by HPLC as described previously (Brunelle et al., 1997) . N-Oxygenation of 5-DPT or chlorpromazine was determined by quantifying the amount of authentic product formed by HPLC. et al., 2003; Guex and Peitsch, 1997; Peitsch, 1995) .
Four PDB (Protein Data Bank) (Berman et al., 2000) structures were selected for homology modeling the structure of human FMO3: glutathione reductase (1get) (Mittl et al., 1994) , NADPH-peroxidase (1npx) (Stehle et al., 1991) , a protein with similarity to flavin-containing monooxygenases (1vqw) (Eswaramoorthy et al., 2006) and phenylacetone monooxygenase (1w4x) (Malito et al., 2004) . Several FMO sequences were involved in the analysis (i.e., including FMO3 of human, rat, cow, bull, chicken and mouse, FMO1 of human, rat and mouse, and rabbit FMO2). Secondary structure was predicted with different methods. 
Data analysis.
Results
Previously, the human FMO3 gene variant Pro 360 -FMO3 was observed only in individuals of African descent, as identified by either MassEXTEND (i.e., a highthroughput chip-based genotype variation detection method) with matrix-assisted laser desorption ionization time-of-flight mass spectrometry described before (Cashman et al., 2001) or by DNA re-sequencing (Lattard et al., 2003) . Previously, it was reported that imipramine and chlorpromazine stimulated the FMO3-dependent S-oxygenation of MMI (Wyatt et al., 1998) . If the Pro 360 amino acid is proximal to the positive regulatory site then alteration of this amino acid could influence FMO-dependent stimulation of substrate oxygenation. Table 3 showed that wild-type FMO3-catalyzed MMI S-oxygenation was stimulated by chlorpromazine. However, of the Leu 360 -FMO3 variants examined, compared to non-stimulated enzyme, none showed a statistically significant stimulation of MMI S-oxygenation on the basis of two-way ANOVA and a Bonferroni post-hoc test. In all cases examined, the degree of stimulation was less than that observed for wild-type FMO3.
Data of Table 4 Molecular modeling of the human FMO3 structure was done in an attempt to understand the possible interaction of the amino acid at position 360 with the NADPH or FAD cofactors. Four PDB structures were selected for homology modeling the structure of human FMO3. Glutathione reductase (1get) and NADPH-peroxidase (1npx) were used because they were used in a previous study (Cashman, 2002b) . Two other structures were suggested by the SWISS-MODEL Template Selection ExPDB database (Schwede et al., 2003; Guex and Peitsch, 1997; Peitsch, 1995) (i.e., a protein with similarity to flavincontaining monooxygenases (1vqw) and phenylacetone monooxygenase (1w4x)). The four PDB structures were manually aligned and superimposed. Two conserved domains of the FAD binding domain and the NADPH binding domain could be found in the superimposed structures (Figure 2 ). With the exception of these domains, the structures were quite divergent. chicken and mouse, FMO1 of human, rat and mouse, and rabbit FMO2). Next, the alignment was done combining the four known substructures with the alignment of the FMOs. The secondary structure elements (α-helix and β-sheets) showed good alignment and considerable sequence similarity in the common structural elements (i.e., FAD and NADPH binding domains). This alignment was used as a starting point for building the human FMO3 model structure and these data were sent to the Swiss-model server and the PromodII program to calculate the 3D model structure of human FMO3 (Schwede et al., 2003; Guex and Peitsch, 1997; Peitsch, 1995) .
The molecular model derived is shown in Figure 3 . Based on the model, Leu 360 lies near but it is not in direct contact with the FAD adenine moiety. The amino acids of the reference structures corresponding to Leu 360 of human FMO3 (i.e., 1get T293, 1vqw
Y325, 1W4X T425, 1NPX T271) also showed that the corresponding amino acid was proximal to the FAD (data not shown).
This article has not been copyedited and formatted. The final version may differ from this version. et al., 1999; Dolphin et al., 2000) . In addition, a detailed examination of structure and function of common allelic variation could also provide insight into mechanistic or structural aspects of FMO action.
In a previous study, a few individuals (i.e., 1 %) were identified as possessing the because it is known that substitution of a Pro into an enzyme can change protein structure. We did observe a significant difference in the effect of 360 amino acid substitution on the thermal stability and half life of Leu 360 -FMO3 variants (Figure 1 ) and we suspect the effect of the 360 loci substitution has a key effect on function.
Accordingly, detailed kinetic studies were undertaken.
We examined variants at the 360 loci to gain insight into structural features that may contribute to increasing the catalytic efficiency of Pro It has been reported that tertiary amines such as chlorpromazine and imipramine stimulate oxygenation of other FMO3 substrates such as MMI (Wyatt et al., 1998) . The data pointed to a regulatory site for FMO3 that facilitated substrate turnover (Cashman, 1995 consequence of changes at loci 360 is quite distinct for MMI and 5-DPT and suggests that these substrates are handled differently by FMO3.
In the presence of 5-DPT, the 360 loci variants and wild-type FMO3 enzymes decreased chlorpromazine N-oxygenation (Table 4) . We interpret this as alternate substrate competitive inhibition of 5-DPT on chlorpromazine N-oxygenation. Previously, we showed that compared to 5-DPT, chlorpromazine was an inferior substrate for FMO3 likely due to the shorter aliphatic side chain associated with this tertiary amine (Lomri et al., 1993) . In contrast, 5-DPT possesses a more optimal aliphatic side chain length to place the tertiary amine further into the substrate binding channel of FMO3 and afford more efficient N-oxygenation. That no stimulation of N-oxygenation of chlorpromazine by 5-DPT was observed and in fact, alternate competitive substrate inhibition was observed, suggests that the mechanism of alternate substrate stimulation is distinct from that of alternative tertiary amine N-oxygenation (or alternative substrate competitive inhibition).
Two FMO models were previously reported (Cashman, 2002b , Ziegler, 2002 using glutathione reductase (Mittl et al., 1994) In summary, for human FMO3, inter-individual variation of enzymatic activity can contribute to discernible differences in drug or chemical metabolism (Cashman and Zhang, 2002) . Genetic polymorphisms of genes encoding FMO enzymes resulting in This article has not been copyedited and formatted. The final version may differ from this version. The oxygenation of chlorpromazine was determined by monitoring the appearance of Noxide associated with the N-oxygenation of chlorpromazine as described in Materials and
Methods.
Data are mean ± standard deviation. Remaining activity
